Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TNF-related apoptosis-inducing ligand level in Alzheimer's disease.

Literature DB >> 19294332

TNF-related apoptosis-inducing ligand level in Alzheimer's disease.

Sermin Genc¹, Mehtap Yuksel Egrilmez, Erdem Yaka, Zahide Cavdar, Leyla Iyilikci, Gorsev Yener, Kursad Genc.

Abstract

In the present study, we determined the significance of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Alzheimer's disease (AD). We characterized the expression of TRAIL protein in the cerebrospinal fluid (CSF) and serum with ELISA and TRAIL mRNA in the peripheral blood mononuclear cells (PBMCs) with real-time PCR in 22 patients with AD and 20 control cases. We could not find TRAIL protein in the CSF samples. The concentration of TRAIL protein in sera from patients with AD was not different from controls. However, there was an inverse correlation between serum TRAIL levels and Mini-Mental State Examination scores in AD patients. Also we did not find significant difference in TRAIL mRNA in the PBMCs of patients with AD when compared with control group. Our data indicate that TRAIL serum level decreases in the late stage of disease.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19294332 DOI： 10.1007/s10072-009-0047-5

Source DB: PubMed Journal: Neurol Sci ISSN： 1590-1874 Impact factor: 3.307

22 in total

1. TRAIL is expressed in the brain cells of Alzheimer's disease patients.

Authors: Daniela Uberti; Giuseppina Cantarella; Fabio Facchetti; Alessia Cafici; Giuseppe Grasso; Renato Bernardini; Maurizio Memo
Journal: Neuroreport Date: 2004-03-22 Impact factor: 1.837

2. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity.

Authors: Daniela Uberti; Giulia Ferrari-Toninelli; Sara Anna Bonini; Ilenia Sarnico; Marina Benarese; Marina Pizzi; Luisa Benussi; Roberta Ghidoni; Giuliano Binetti; PierFranco Spano; Fabio Facchetti; Maurizio Memo
Journal: Neuropsychopharmacology Date: 2006-08-16 Impact factor: 7.853

3. Diagnosis of Alzheimer's disease.

Authors: Z S Khachaturian
Journal: Arch Neurol Date: 1985-11

4. Alzheimer's disease. A metabolic systems degeneration?

Authors: J P Blass; A Zemcov
Journal: Neurochem Pathol Date: 1984

5. Interferon gamma and lipopolysaccharide upregulate TNF-related apoptosis-inducing ligand expression in murine microglia.

Authors: Sermin Genc; Sefa Kizildag; Kursad Genc; Halil Ates; Nese Atabey; Sefa Kizyldag
Journal: Immunol Lett Date: 2003-02-03 Impact factor: 3.685

Review 6. Neuropathological stageing of Alzheimer-related changes.

Authors: H Braak; E Braak
Journal: Acta Neuropathol Date: 1991 Impact factor: 17.088

7. Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients.

Authors: Johanna Ojala; Irina Alafuzoff; Sanna-Kaisa Herukka; Thomas van Groen; Heikki Tanila; Tuula Pirttilä
Journal: Neurobiol Aging Date: 2007-07-20 Impact factor: 4.673

8. Peripheral cytokine release in Alzheimer patients: correlation with disease severity.

Authors: Gessica Sala; Gloria Galimberti; Carla Canevari; Maria Elisabetta Raggi; Valeria Isella; Maurizio Facheris; Ildebrando Appollonio; Carlo Ferrarese
Journal: Neurobiol Aging Date: 2003-11 Impact factor: 4.673

9. Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity.

Authors: G Cantarella; D Uberti; T Carsana; G Lombardo; R Bernardini; M Memo
Journal: Cell Death Differ Date: 2003-01 Impact factor: 15.828

10. p38 mitogen-activated protein kinase modulates expression of tumor necrosis factor-related apoptosis-inducing ligand induced by interferon-gamma in fetal brain astrocytes.

Authors: J Lee; J-S Shin; J Y Park; D Kwon; S-J Choi; S-J Kim; I-H Choi
Journal: J Neurosci Res Date: 2003-12-15 Impact factor: 4.164

13 in total

1. A new TRAIL in Alzheimer's disease therapy.

Authors: Dan Frenkel
Journal: Brain Date: 2015-01 Impact factor: 13.501

2. Circulating Dkk1 and TRAIL Are Associated With Cognitive Decline in Community-Dwelling, Older Adults With Cognitive Concerns.

Authors: Ryan D Ross; Raj C Shah; Sue Leurgans; Teodoro Bottiglieri; Robert S Wilson; Dale Rick Sumner
Journal: J Gerontol A Biol Sci Med Sci Date: 2018-11-10 Impact factor: 6.053

TNF-related apoptosis-inducing ligand level in Alzheimer's disease.

1. TRAIL is expressed in the brain cells of Alzheimer's disease patients.

2. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity.

3. Diagnosis of Alzheimer's disease.

4. Alzheimer's disease. A metabolic systems degeneration?

5. Interferon gamma and lipopolysaccharide upregulate TNF-related apoptosis-inducing ligand expression in murine microglia.

Review 6. Neuropathological stageing of Alzheimer-related changes.

7. Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients.

8. Peripheral cytokine release in Alzheimer patients: correlation with disease severity.

9. Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity.

10. p38 mitogen-activated protein kinase modulates expression of tumor necrosis factor-related apoptosis-inducing ligand induced by interferon-gamma in fetal brain astrocytes.

1. A new TRAIL in Alzheimer's disease therapy.

2. Circulating Dkk1 and TRAIL Are Associated With Cognitive Decline in Community-Dwelling, Older Adults With Cognitive Concerns.

3. Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease.

4. A Study of the Impact of Death Receptor 4 (DR4) Gene Polymorphisms in Alzheimer's Disease.

5. Increased inflammation in BA21 brain tissue from African Americans with Alzheimer's disease.

6. Alzheimer's disease: a step closer to understanding type 3 diabetes in African Americans.

7. Shared Genetic Etiology between Alzheimer's Disease and Blood Levels of Specific Cytokines and Growth Factors.

Review 8. Clinical perspectives of TRAIL: insights into central nervous system disorders.

9. Alterations of the Neuroinflammatory Markers IL-6 and TRAIL in Alzheimer's Disease.

10. Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia.